Redeye provides a short research update following the outcome of the TO3 warrants recently published by Coegin Pharma. We are encouraged by the high subscription rate and the much-needed capital injection. Having adjusted for the outcome of the warrants, we revise our fair value range with an adjusted base case of SEK9 (10).